tislelizumab
beigene,novartis
$bgne beigene announces late-breaking data at esmo gi showing overall survival benefit for tislelizumab plus chemotherapy in first-line advanced or metastatic esophageal squamous cell carcinoma 
Be the First to Know Which #PennyStocks Are Being Promoted - Not the Last! Real-Time #StockAlert Tracking and Monitoring: https://t.co/WLRj8z0R5p